ClinicalTrials.Veeva

Menu
C

Centrum Kliniczno Badawcze | Elblag, Poland

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Guselkumab
CHS-0214
Ralfinamide
Secukinumab
Semaglutide
Enbrel
Filgotinib
CNTO 1959
Golimumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 12 total trials

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis (OLINGUITO)

This study is comparing 200 milligrams (mg) of filgotinib a day with a placebo to see if filgotinib helps to treat Axial Spondyloarthritis (axSpA) an...

Active, not recruiting
Axial Spondyloarthritis
Drug: Placebo
Drug: Filgotinib

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate re...

Active, not recruiting
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab
Status recently updated

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular...

Enrolling
Active, not recruiting
Cardiovascular Disease
Drug: Semaglutide
Drug: Cagrilintide

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Placebo (Ziltivekimab B)
Drug: Placebo (Ziltivekimab C)

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Novo Nordisk logo
A
C
Janssen (J&J Innovative Medicine) logo
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems